Capital Research Global Investors
INBX

Capital Research Global Investors’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Capital Research Global Investors’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-712,360
Closed -$27.1M – 435
2023
Q4 		$27.1M Sell
712,360
-509,361
-42% -$10.9M 0.01% 357
2023
Q3 		$22.4M Sell
1,221,721
-530,192
-30% -$11.1M 0.01% 362
2023
Q2 		$45.5M Hold
1,751,913
– – 0.01% 331
2023
Q1 		$33.1M Buy
+1,751,913
New +$40.7M 0.01% 351

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Capital Research Global Investors's INBX Position: Q1 2024 in Review

Capital Research Global Investors sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2024, closing a stake of 712,360 shares — an estimated $27.1M sold.

Capital Research Global Investors first reported a position in INBX in Q1 2023 and held it in 4 quarters. The position peaked at $45.5M in Q2 2023. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

  • Capital Research Global Investors reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Capital Research Global Investors sold 712,360 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $27.1M.
  • Capital Research Global Investors first reported a position in Inhibrx, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
  • Capital Research Global Investors's Inhibrx, Inc. Common Stock position peaked at $45.5M in Q2 2023.
  • 126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Capital Research Global Investors's 13F filing for Q1 2024, filed 14 May 2024.